Categories
Pharmaceutical

North America’s Demand for C-kit/CD117 Tests Is Anticipated to Account for Nearly US$ 800 Mn In Revenues by 2022-end

Big data and analytics will drive patient outcomes in a big way, and the coming years will witness a growing emphasis on healthcare service providers in the business of gathering and processing patient health data.

The global demand for colorectal cancer diagnostics is anticipated to exhibit an impressive expansion at a CAGR of 8.5% during the forecast period 2017 to 2022, according to a report by Fact.MR. Global revenues from the market are projected to surpass US$ 2,000 Mn by 2022-end.

For detailed insights on enhancing your product footprint, request for a sample here-
https://www.factmr.com/connectus/sample?flag=S&rep_id=70

Market Taxonomy

Test Type End User
FOB Hospital Associated Labs
CTC Tests Independent Diagnostic Laboratories
BRAF V600 Mutations Cancer Research Institutes
CEA Tests Others
C-kit/CD117
KRAS Mutation Tests
Immunohistochemistry
Others

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

Speak to Research Analyst:
https://www.factmr.com/checkout/70

According to the World Cancer Research Fund, colorectal cancer forms the third-most occurring type of cancer across the globe. In 2012, over 1 Mn cases of colorectal cancer were diagnosed. Majority of these cases were reported across developed economies, and this is further estimated to exceed in the near future. This rise in incidences of colorectal cancer has boosted demand for its diagnostics, treatment, and therapeutics worldwide. However, the number of deaths owing to colorectal cancer has been witnessing a decline since recent past, owing to the awareness spread by the American Cancer Society. The introduction of more effective diagnostics, and development of screening methods are further expected to drive growth of the global colorectal cancer diagnostics market.

The advent of new diagnostic tests, increasing uptakes of diagnosis-associated therapies, and initiatives taken by private as well as government organisations are some factors expected to propel growth of the global market for colorectal cancer diagnostics. Increasing unmet requirements across several emerging economies, coupled with the absence of neoadjuvant and adjuvant pipeline agents for diagnosing high-risk patients affected with resectable colorectal cancer is expected to create huge growth opportunities for leading players in the market. However, factors such as growing reluctance towards medications of colorectal cancer by patients, and unawareness across several remote regions of the globe is expected to inhibit the market growth.

For More Insights:
https://www.biospace.com/article/increasing-demand-from-cosmetic-and-semiconductor-industries-is-shaping-growth-of-in-situ-particle-measurement-market-fact-mr/

6 Key Projections for the Global Colorectal Cancer Diagnostics Market

  1. North America will continue to be the most lucrative region for the colorectal cancer diagnostics market. Revenue from market in North America is expected to surpass US$ 800 Mn by 2022-end.
  2. The colorectal cancer diagnostics market in Asia Pacific excluding Japan (APEJ) is expected to register the fastest expansion during the forecast period. However, revenue from the market in Middle East & Africa (MEA) will continue to be sluggish during the forecast period.
  3. By test type, FOB will continue to be the largest adopted test for diagnosis of colorectal cancer across the globe. Revenue from FOB tests for colorectal cancer diagnostics will remain largest, followed by CTC tests.
  4. Immunochemistry tests for colorectal cancer diagnostics will exhibit the highest CAGR through 2022. However, revenue from BRAF tests will remain the lowest in the global colorectal cancer diagnostics market during the forecast period.
  5. On the basis of end-users, although hospital-associated labs will remain sought-after in the market, cancer research institutes will continue to register the fastest expansion during the forecast period.
  6. Revenues from hospital-associated labs for colorectal cancer diagnostics are expected to reach nearly US$ 1,000 Mn by 2022-end. Independent diagnostic laboratories will continue to be the second most lucrative end-users in the global colorectal cancer diagnostics market.

Need more information about Report Methodology? Click here-
https://www.factmr.com/connectus/sample?flag=RM&rep_id=70

The report also includes a comprehensive landscape of global market for colorectal cancer diagnostics, where companies namely

Illumina, Inc.
Foundation Medicine, Inc.
Sysmex Corporation
Cancer Genetics, Inc.
Danaher Corporation
Biocept, Inc
Pathway Genomics Corporation
Rosetta Genomics
Epigenomics AG
Exact Science Corporation

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Leave a Reply

Your email address will not be published. Required fields are marked *